OptimUM-01
Source
Journal of Clinical Oncology 2026 McKean et al.
Publications
PKC Inhibition in UM (darovasertib)
Darovasertib is a potential first-in-class oral, small-molecule inhibitor of PKC. It is being evaluated in multiple clinical trials in uveal melanoma, including in combination with crizotinib, an oral inhibitor of c-MET, in patients with metastatic disease and as an adjuvant therapy in the pre-metastatic setting. IDEAYA is also evaluating single-agent darovasertib as a neoadjuvant therapy in primary uveal melanoma.
OptimUM-01
Source
ESMO 2026 McKean et al.
Darovasertib and crizotinib for HLA-A*02-positive metastatic uveal melanoma: Results from the Phase 2 OptimUM-01 study
Read more (opens in a new tab)OptimUM-01
Source
SMR 2025 McKean et al.
First reported overall survival results from a Phase 1/2 study of darovasertib plus crizotinib as first-line treatment for metastatic uveal melanoma (OptimUM-01)
Read more (opens in a new tab)OptimUM-01
Source
ESMO 2023 McKean et al.
ctDNA reduction and clinical efficacy of the darovasertib + crizotinib combination in metastatic uveal melanoma
Read more (opens in a new tab)OptimUM-02
Source
ESMO 2026 Piperno-Neumann et al.
Darovasertib with crizotinib vs investigator's choice as first-line treatment for patients with HLA-A2 negative metastatic uveal melanoma (OptimUM-02): A subgroup analysis.
Read more (opens in a new tab)OptimUM-02
Source
ASCO 2026 Orloff et al.
Darovasertib plus crizotinib vs investigator's choice as first-line treatment for patients with HLA-A2 negative metastatic uveal melanoma: Primary results from the OptimUM-02 trial
Read more (opens in a new tab)OptimUM-09
Source
ESMO 2026 Shackleton et al.
